EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative analysis of low- and high-dose apheresis platelets in platelet-refractory patients with hematologic malignancies

Suvetha Rajendran, Ratti Ram Sharma, Rekha Hans, Pankaj Malhotra, Divjot Sing Lamba

Hematology, Transfusion and Cell Therapy · 2026-10 · 48 (4) · 106538

DOI: 10.1016/j.htct.2026.106538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology, Transfusion and Cell Therapy, 2026-10. Verfasst von Suvetha Rajendran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Postgraduate Institute of Medical Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Alloimmunization-induced platelet transfusion refractoriness represents a major clinical challenge in hematology-oncology. Optimal strategies for platelet support in this population remain to be established. OBJECTIVE: This study aimed to compare the efficacy of low-dose crossmatched versus high-dose uncrossmatched single donor apheresis platelets (SDAP) in platelet-refractory patients with hematologic malignancies by assessing corrected count increment (CCI), percent platelet recovery (PPR), and post-transfusion platelet increment (PPI). MATERIALS AND METHODS: Forty alloimmunized, platelet-refractory patients were enrolled. Solid phase red cell adherence assay was used for crossmatching and alloimmunization detection. Patients received low-dose crossmatched SDAP (1.49 ± 0.30 × 1011 platelets/unit) followed by high-dose uncrossmatched SDAP (4.9 ± 1.0 × 1011 platelets/unit) at the subsequent transfusion. The CCI, PPR %, PPI, transfusion intervals, and World Health Organization bleeding grades were recorded and compared after each transfusion. RESULTS: The CCI and PPR% were significantly higher following low-dose crossmatched SDAP compared to standard-dose SDAP (p-value

Schlagwörter

Stichwörter der Autor:innen

AlloimmunizationCrossmatchPlatelet refractorinessPlatelet transfusionSingle donor apheresis

Autor:innen und Institutionen

  • Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Electronic address: rrsdoc@hotmail.com.
  • Department of Clinical Hematology and Medical Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Förderung

  • Postgraduate Institute of Medical Education and Research

Zitieren

APA

Rajendran, S., Sharma, R. R., Hans, R., Malhotra, P., & Lamba, D. S. (2026). Comparative analysis of low- and high-dose apheresis platelets in platelet-refractory patients with hematologic malignancies. Hematology, Transfusion and Cell Therapy, 48(4), 106538. https://doi.org/10.1016/j.htct.2026.106538

Vancouver

Rajendran S, Sharma RR, Hans R, Malhotra P, Lamba DS. Comparative analysis of low- and high-dose apheresis platelets in platelet-refractory patients with hematologic malignancies. Hematology, Transfusion and Cell Therapy. 2026;48(4):106538. doi:10.1016/j.htct.2026.106538

BibTeX
@article{Rajendran2026,
  author = {Rajendran, Suvetha and Sharma, Ratti Ram and Hans, Rekha and Malhotra, Pankaj and Lamba, Divjot Sing},
  title = {Comparative analysis of low- and high-dose apheresis platelets in platelet-refractory patients with hematologic malignancies},
  journal = {Hematology, Transfusion and Cell Therapy},
  year = {2026},
  volume = {48},
  number = {4},
  pages = {106538},
  doi = {10.1016/j.htct.2026.106538}
}
Kostenlos starten →